Global Cycloplegic Agents Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Cycloplegic Agents market size was valued at US$ 1494 million in 2024 and is forecast to a readjusted size of USD 2230 million by 2031 with a CAGR of 6.0% during review period.

Cycloplegic agents act by paralysing the iris"s sphincter muscle, causing dilation, and by paralysing the ciliary muscle, which inhibits accommodation. Atropine, homatropine, scopolamine, cyclopentolate, and tropicamide are examples of cycloplegic agents. Preventing movement of the iris or ciliary body"s dilator and sphincter muscles with cycloplegic drugs often relieves pain in inflammatory conditions such as uveitis and is a standard therapeutic procedure. Furthermore, as a result of the local release of prostaglandins, the iris usually constricts during irritation or inflammation. This makes it easier for adhesions to form with the lens. Cycloplegics also aid in the prevention of this complication.

Cycloplegic drugs are muscarinic receptor blockers. Atropine, cyclopentolate, homatropine, scopolamine and tropicamide are among them. They are approved for use in cycloplegic refraction (paralysing the ciliary muscle to determine the true refractive error of the eye) and uveitis treatment. These are the factors which is expected to grow of the market.

This report is a detailed and comprehensive analysis for global Cycloplegic Agents market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Cycloplegic Agents market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Cycloplegic Agents market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Cycloplegic Agents market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Cycloplegic Agents market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Cycloplegic Agents

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Cycloplegic Agents market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, Henry Schein, Inc, Actiza Pharmaceutical Private Limited, Hameln Pharma Gmbh, Sigma Pharmaceuticals, LLC, Biomedica, Prudence Pharma Chem, Heer Pharma Pvt. Ltd, Fresenius Kabi AG, Bausch Health Companies, Inc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Cycloplegic Agents market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Atropine

Cyclopentolate

Houmatopin

Tropicamide

Scopolamine

Market segment by Application

Pseudomyopia

Optometry

Uveitis

Other

Major players covered

Pfizer Inc

Henry Schein, Inc

Actiza Pharmaceutical Private Limited

Hameln Pharma Gmbh

Sigma Pharmaceuticals, LLC

Biomedica

Prudence Pharma Chem

Heer Pharma Pvt. Ltd

Fresenius Kabi AG

Bausch Health Companies, Inc

Novartis

Alcon Inc

Akorn, Inc

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Cycloplegic Agents product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Cycloplegic Agents, with price, sales quantity, revenue, and global market share of Cycloplegic Agents from 2020 to 2025.

Chapter 3, the Cycloplegic Agents competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cycloplegic Agents breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Cycloplegic Agents market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Cycloplegic Agents.

Chapter 14 and 15, to describe Cycloplegic Agents sales channel, distributors, customers, research findings and conclusion.